Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Posoleucel · 1 trial · 6 indications
The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV through Week 14
| Arm | Type | Description |
|---|---|---|
| Posoleucel (ALVR105) | EXPERIMENTAL | Administered as 2-4 milliliter infusion |
| Name | Type | Description |
|---|---|---|
| Posoleucel (ALVR105) | BIOLOGICAL | Administered as 2-4 milliliter infusion |
Key Inclusion Criteria * ≥1 year of age at the day of screening visit. * Either no evidence of viral infection or viremia, or asymptomatic, viral infection with 3 or fewer viruses of interest at time of screening * Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clin...
Posoleucel is an investigational monoclonal antibody being developed for the prevention of adenovirus infection. It is also being studied for the prevention of BK virus, cytomegalovirus, Epstein-Barr virus, human herpes virus-6, and JC virus infections in patients who have undergone allogeneic hematopoietic cell transplant.
Posoleucel is being developed by Kalaris Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol KLRS.
Posoleucel is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in any active clinical trials.
Posoleucel has been studied in one completed Phase 2 clinical trial, identified as NCT04693637. This trial evaluated Posoleucel for multi-virus prevention in patients post-allogeneic hematopoietic cell transplant, enrolling 26 participants in the United States.
Yes, Posoleucel is also known as ALVR105 and was formerly called Viralym-M. The completed clinical trial NCT04693637 was titled "Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant."